Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs—the Industry Takes Notice
IRVINE, Calif., October 23, 2026 – GATC Health has been selected by Vistagen to apply our Operon® AI platform and Derisq® risk prediction capabilities to Vistagen’s Phase 2 and Phase 3 pipeline to support of its neuroscience therapies. Vistagen is using our end-to-end biological simulations to generate strategic insights for its clinical-stage programs: fasedienol (social anxiety disorder), itruvone (major depressive disorder), and refisolone (menopausal hot flashes).
This engagement shows how Operon is being used to inform both business and science decisions for a Nasdaq-listed biopharmaceutical company, and reflects growing confidence in the role our predictive models can play in real-world drug development.
As noted below, the announcement immediately captured industry and investor attention across major financial and biotech syndications:
- Yahoo Finance: Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
- BioSpace: Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
- Morningstar: Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
- Investing.com: Vistagen partners with GATC Health on AI drug development